The outcome of a sustained decrease in eGFR (≥50%) from randomisation has been widely used to explore effects on kidney disease progression in subanalyses of the DAPA-CKD trial.1, 8, 10, 22, 23 This definition appears to be more specific for progression to kidney failure than lower thresholds for sustained decreases in eGFR (eg, ≥30% or ≥40%) when assessing interventions with a negative acute dip effect on eGFR, such as SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and kidney failure.